Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by CEL-SCI Corporation

< Previous 1 2 3 Next >
Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI’s Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI’S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Announces Reddit AMA with Geert Kersten
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation to Present at LD Micro Invitational
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Publication of ASCO 2022 Abstracts
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Reports Second Quarter Fiscal 2022 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Acceptance of Abstracts to ASCO 2022
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Reports First Quarter Fiscal 2022 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Reports Fiscal 2021 Financial Results and Clinical & Corporate Developments
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
Discussion of Results of CEL-SCI’s Phase 3 Trial Is Now Available
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI’s Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder Meeting
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS